Prasugrel Intellectual Bias: FDA Makes Changes, Congress Demands Answers

Recent improvements to FDA's screening process for intellectual conflicts of interest among advisory committee members are likely to be part of the agency's response to a congressional inquiry into the review of Lilly's prasugrel (Effient)